3 results
Primary: To provide metastatic colorectal cancer patients with access to aflibercept and todocument the overall safety in these patientsSecondary: To document the Health-Related Quality of Life of aflibercept in this patientpopulation
Primary objective1. To test the safety of cold plasma treatment: SAE in * 10% of participants, no pain (VAT * 2) and no local skin reaction: redness, blister formation, pain or itching. Secondary objectives:The effect of cold plasma treatment on : 1…
To prospectively explore the feasibility safety, tolerability, preliminary efficacy, costs, and pharmacokinetic profile of repetitive ePIPAC-OX as a palliative monotherapy for isolated unresectable colorectal PM under controlled circumstances.